Due diligence profile on Andrew Greenfield, retired Abiomed president. Examines FDA Class I recalls, warning letter, resolved lawsuit, and corporate-vs-personal risk distinction.
Retired Worldwide President, Abiomed Inc. / Johnson & Johnson MedTech | Section 16 Officer | Named Executive Officer
Primary Jurisdictions
United States (Massachusetts; First Circuit)
Investigation Period
2005 – 2025
Methodology
OSINT investigation conducted across 10 structured search angles including: court record retrieval (PACER / FindLaw / Justia), FDA primary source review (FDA.gov recall database and warning letter index), SEC EDGAR insider filing review, trade press corroboration (MassDevice, MedTech Dive), LinkedIn profile review, Salary.com proxy pointer, and structured adverse-media sweep. Anonymous tip material classified as UNVERIFIED and excluded from citeable evidence. Gripeo-style adverse-SEO artifact identified, archived, and excluded from evidentiary use.
Key findings from the OSINT investigation. All allegations are unproven unless legally established.
Andrew J. Greenfield is a low-individual-risk subject embedded within a high-adversity corporate regulatory environment. The only legal proceeding directly naming his executive role — Suzuki v. Abiomed Inc. — was resolved entirely in his favor at both the district and First Circuit appellate level in 2019 and is fully dormant. Abiomed Inc. as a corporate entity accumulated significant FDA enforcement actions during his 2022–2025 presidency, including four Class I recalls and a warning letter, but no personal enforcement nexus has been identified. A Gripeo-style adverse-SEO artifact presents a medium false-positive risk for automated compliance screening and should be treated as non-evidentiary.
Andrew J. Greenfield is the recently retired Worldwide President of Abiomed Inc., now operating as Johnson & Johnson MedTech Heart Recovery, and the maker of the Impella cardiac pump — the world's smallest heart pump platform. Greenfield joined Abiomed in 2005 as Vice President of Healthcare Solutions, progressed to Executive Vice President and Chief Compliance Officer, and was appointed Worldwide President in 2022 following Johnson & Johnson's acquisition of Abiomed in December 2022. He served as a Section 16 Officer and named executive officer, with formal insider-reporting obligations filed with the SEC via Form 4 through EDGAR. His successor, Devi Govender, was named Worldwide President of Heart Recovery in March 2025, confirming Greenfield's retirement after approximately 20 years with the organization. [VERIFIED PUBLIC — Abiomed.com biography; LinkedIn; SEC EDGAR Form 4 / power of attorney filing.]
The only legal proceeding directly implicating Greenfield's named executive role is Suzuki v. Abiomed, Inc., an employment dispute filed in late 2016 by former Asia-region executive Keisuke Suzuki alleging breach of implied covenant of good faith and fair dealing, in which Greenfield was identified as the senior Abiomed executive who conducted performance reviews and delivered termination-related communications. The U.S. District Court for the District of Massachusetts granted summary judgment entirely in Abiomed's and Greenfield's favor, and the First Circuit Court of Appeals affirmed that ruling in full on November 27, 2019. The matter is fully resolved and dormant, with no finding of wrongdoing against Greenfield in any form. Separately, Abiomed as a corporate entity accumulated a material FDA enforcement record during Greenfield's final years as Worldwide President — including a September 2023 FDA warning letter, four Class I recalls in 2023, and a December 27, 2023 Class I labeling recall associated with 129 serious injuries and 49 deaths across 66,390 distributed pumps — but no personal enforcement action, criminal charge, regulatory sanction, or financial-crime allegation against Greenfield individually has been identified across any search angle. This dossier's analytical value lies in accurately mapping that corporate-vs-individual risk boundary for due-diligence consumers.
Individual Adverse Proceedings
Suzuki v. Abiomed Inc. — the sole identified proceeding directly implicating Greenfield's executive role. Resolved entirely in his favor at both district and First Circuit appellate level, November 27, 2019. Dormant.
Corporate Class I Recalls (2023, during presidency)
Four Class I recalls — FDA's most serious classification — issued against Abiomed Inc. as corporate entity across 2023, including the December 27, 2023 labeling recall affecting 66,390 pumps. Attributed to Abiomed Inc.; no personal enforcement nexus to Greenfield identified.
Personal Enforcement Actions Identified
Zero personal enforcement actions, criminal charges, regulatory sanctions, financial-crime allegations, or civil proceedings beyond the resolved Suzuki matter have been identified against Andrew J. Greenfield across all 10 structured search angles.
Risk Classification
Based on AML exposure, offshore structures & PEP associations
Insufficient publicly available information exists regarding Andrew J. Greenfield's family structure, personal relationships, or domestic connections. No family members have been identified as co-directors, beneficial owners, nominees, or parties to any legal or regulatory proceeding connected to his professional activities. No family-linked entity use, related-party transaction, or nepotism concern has been surfaced across any search angle.
No PEP (politically exposed person) adjacency through family or spousal relationships has been identified. No financial entanglement between Greenfield's personal or familial connections and the entities under investigation — Abiomed Inc. or Johnson & Johnson MedTech — has been surfaced in available public records, SEC proxy filings, or court documents reviewed for this dossier.
Abiomed Inc. — VP Healthcare Solutions (2005–c.2018)
VERIFIED PUBLIC. Greenfield joined Abiomed in 2005 as Vice President of Healthcare Solutions, establishing his initial accountability scope within the company's commercial and clinical support operations. This role predates the Impella platform's major U.S. market expansion and the company's emergence as a named executive officer reporting entity under SEC proxy disclosure rules. [Source: Abiomed.com official biography; SEC EDGAR power of attorney filing 2016.]
Abiomed Inc. — Executive Vice President and Chief Compliance Officer (c.2018–2022)
VERIFIED PUBLIC (with proxy confirmation gap). Greenfield's progression to EVP and CCO placed him in direct organizational accountability for Abiomed's compliance function during a period that overlaps with the commercial launch of the Impella Connect remote monitoring system — the product subsequently flagged by the FDA as having been marketed without proper premarket authorization. The precise start date of this role and the exact scope language used in DEF 14A proxy filings remain an open evidence gap pending direct EDGAR proxy retrieval. INFERRED (labeled): As CCO, organizational accountability for regulatory compliance systems would ordinarily encompass premarket submission oversight. No personal enforcement nexus has been identified. [Source: Abiomed.com official biography; SEC EDGAR pointer via Salary.com DEF 14A reference.]
Abiomed Inc. / Johnson & Johnson MedTech — Worldwide President (2022–early 2025)
VERIFIED PUBLIC. Greenfield's appointment as Worldwide President coincided with Johnson & Johnson's December 2022 acquisition of Abiomed. His tenure as President encompassed the entirety of Abiomed's documented 2023 FDA enforcement period: the September 2023 warning letter, four Class I recalls, and the December 27, 2023 labeling recall covering 66,390 Impella left-sided blood pumps. INFERRED (labeled): As Worldwide President during this period, Greenfield held senior organizational accountability for the quality and regulatory affairs functions implicated by FDA enforcement. No personal enforcement action has been identified. [Source: Abiomed.com biography; MedTech Dive; MassDevice; FDA.gov recall database.]
Section 16 Insider — Abiomed Inc. (SEC-reported executive officer status)
VERIFIED PUBLIC. SEC EDGAR confirms Greenfield held Section 16 Officer status at Abiomed, triggering mandatory Form 4 insider transaction reporting obligations. A power of attorney filing (EDGAR accession 0001179110-16-022218) confirms his formal reporting officer designation as of 2016. Proxy filings (DEF 14A) identified as referencing Greenfield as a named executive officer via Salary.com pointer. Direct retrieval of proxy accountability scope language and Form 4 transaction records for 2021–2023 remains an open evidence gap. [Source: SEC EDGAR filing; Salary.com proxy pointer.]
Industry Leadership — DeviceTalks Boston / MassDevice Keynote Platform
REPORTED. MassDevice reporting confirms Greenfield's public-facing executive identity included keynote appearances and industry association participation consistent with his role as Worldwide President of a major cardiac device company. His successor Devi Govender was confirmed as keynoting DeviceTalks Boston in connection with her appointment as Worldwide President of Heart Recovery in March 2025. This participation reflects the public professional identity Greenfield maintained throughout his tenure. [Source: MassDevice; LinkedIn.]
Retirement and Succession — Devi Govender Named Successor (March 2025)
VERIFIED PUBLIC. Greenfield's planned retirement from the Worldwide President role was publicly announced and confirmed through his LinkedIn profile and trade press coverage. Devi Govender was named as his successor as J&J's Worldwide President of Heart Recovery in March 2025. The primary sourcing vehicle for the retirement announcement (press release, SEC 8-K, or LinkedIn post) has not been independently retrieved and remains an open evidence gap. No publicly disclosed separation agreement or equity acceleration language has been identified. [Source: LinkedIn; MassDevice.]
Click an event for full details
Select a milestone to view details
VERIFIED PUBLIC. Greenfield joined Abiomed Inc. in 2005 as Vice President of Healthcare Solutions, beginning a 20-year tenure at the cardiac device manufacturer. This entry-level executive role established his foundational accountability within the company's commercial and clinical support infrastructure. [Source: Abiomed.com official biography.]
Career Overview
Organizational context mapping — Greenfield's corporate relationships within Abiomed and J&J MedTech. No adverse network identified. All relationships are professional or procedural.
Not applicable
No Russian-nexus entity or relationship has been identified for Andrew J. Greenfield. This field is populated to satisfy schema requirements only.
Not applicable
No offshore, Russian, or sanctioned-jurisdiction entity connection has been identified across any search angle.
Not applicable
Insufficient publicly available information regarding any Russian or CIS-jurisdiction business relationship.
Not applicable — European operations context only
Abiomed's Impella devices were subject to CE mark and European market distribution, but no European regulatory enforcement action against Greenfield or Abiomed has been identified in the scope of this investigation.
Japan PMDA — Impella Approval (Sep 2016) — UNVERIFIED TIP
UNVERIFIED. Anonymous tip material references a September 2016 PMDA approval for Impella devices with restricted indications. This has not been independently corroborated against PMDA primary sources and is recorded here as an open evidence gap, not a verified finding.
Not applicable
Insufficient publicly available information regarding any other European-jurisdiction regulatory or legal proceeding involving Greenfield individually.
Tap an entity to view details · Drag slider to explore changes over time
Greenfield joins Abiomed
Select an entity
Click any node to view entity details, jurisdiction, and ownership notes.
Interactive visualization of alleged shell company operators and their network of liquidated entities. Click an operator to highlight connections.
0
Total Director Roles
0
Total Founder Roles
Not applicable — no shell network identified
Liquidation Rate
Not applicable — no offshore or shell financial activity identified
Reported Financial Activity
Form 4 Insider Transaction Gap
2021–2023 window unreviewed
SEC Form 4 filings covering the recalled device distribution period not directly retrieved. Review recommended.
No Offshore Structure Identified
Confirmed negative finding
No shell company, offshore entity, or nominee arrangement has been identified or alleged across all search angles.
Proxy Filing Accountability Scope Gap
DEF 14A language not retrieved
Direct retrieval of DEF 14A proxy filings required to confirm accountability scope language across role transitions.
Key Concern
No beneficial ownership concealment, offshore structure, or nominee arrangement has been identified for Andrew J. Greenfield. The principal open gap is the direct retrieval of SEC Form 4 insider transaction filings for the 2021–2023 recalled device distribution window, which would allow determination of whether any equity dispositions occurred proximate to FDA enforcement events. This gap is documented as a known unknown; no adverse finding is implied.
VERIFIED PUBLIC — NEGATIVE FINDING. Andrew J. Greenfield does not qualify as a Politically Exposed Person (PEP) under standard AML/KYC classification frameworks. He is a commercial medical device executive with no identified current or prior government role, political party affiliation, elected or appointed public office, international organization position, or state-owned enterprise directorship. No PEP adjacency through family or close associate relationships has been identified. No OFAC designation, Treasury SDN list entry, or sanctions screening hit has been identified across any search angle.
VERIFIED PUBLIC — NEGATIVE FINDING. No sanctions list entry (OFAC, EU, UN, OFSI, or equivalent) has been identified for Andrew J. Greenfield. No financial-crime designation, AML referral, Anti-Kickback Statute enforcement, False Claims Act action, or FCPA proceeding naming Greenfield individually has been identified. No state professional license or medical board action has been identified. These negative findings are documented as closed search angles, not as presumptions of clearance — formal screening against live sanctions databases is recommended for any compliance-critical engagement.
Suzuki v. Abiomed Inc. — Employment Dispute (RESOLVED — FULLY IN GREENFIELD'S FAVOR)
VERIFIED PUBLIC. The sole identified legal proceeding directly implicating Greenfield's named executive role. Keisuke Suzuki, a former Abiomed Asia-region executive, filed suit in late 2016 alleging breach of the implied covenant of good faith and fair dealing and related claims, asserting approximately $2 million in damages. Greenfield was identified in the complaint as the senior Abiomed executive who conducted Suzuki's performance reviews and delivered termination-related communications. The U.S. District Court for the District of Massachusetts granted summary judgment entirely in Abiomed's and Greenfield's favor. The First Circuit affirmed in full on November 27, 2019 (No. 19-1233). The matter is fully resolved and dormant. No finding of wrongdoing against Greenfield in any form. [VERIFIED PUBLIC — FindLaw; Justia; MassDevice. Evidence class: VERIFIED PUBLIC.]
Abiomed FDA Warning Letter (September 2023) — CORPORATE LEVEL ONLY
VERIFIED PUBLIC — ATTRIBUTED TO ABIOMED INC. AS CORPORATE ENTITY. FDA issued a warning letter to Abiomed Inc. in September 2023, finding: (1) failure to adequately report quality problems with Impella devices; and (2) marketing of the Impella Connect remote monitoring system without proper premarket authorization. 46 products had been recalled since J&J's December 2022 acquisition. INFERRED (labeled): As Worldwide President, Greenfield held organizational accountability for quality and regulatory affairs functions during this period. No personal enforcement action, regulatory sanction, or civil proceeding establishing individual liability has been identified. Direct FDA.gov warning letter URL is an open evidence gap. [VERIFIED PUBLIC via MedTech Dive; INFERRED — organizational accountability only.]
Abiomed Impella Class I Recalls (2023) — CORPORATE LEVEL ONLY
VERIFIED PUBLIC — ATTRIBUTED TO ABIOMED INC. AS CORPORATE ENTITY. Four Class I recalls — FDA's most serious classification — were issued against Abiomed in 2023. The most consequential: a December 27, 2023 labeling recall for Impella left-sided blood pumps covering 66,390 pumps distributed October 2021–October 2023, associated with 129 serious injuries including 49 deaths related to catheter perforation risk and inadequate labeling warnings. INFERRED (labeled): Greenfield held organizational accountability as Worldwide President during the full distribution and recall initiation period. No personal enforcement nexus has been identified. [VERIFIED PUBLIC — FDA.gov recall notice; MassDevice; MedTech Dive. Adverse event figures: FDA primary source.]
Impella Product-Liability Litigation Wave (2023–2025) — CORPORATE LEVEL ONLY
REPORTED. Ongoing product-liability civil litigation related to alleged Impella device defects and patient deaths/injuries is documented in trade press as of mid-2025. The scope of active cases, any MDL consolidation proceedings, and lead plaintiff counsel structure have not been fully established in this investigation and constitute an open evidence gap. CONFIRMED NEGATIVE: No product-liability case personally naming Andrew Greenfield as a defendant has been identified. All identified litigation is attributed to Abiomed Inc. and/or Johnson & Johnson MedTech as corporate defendants. [REPORTED — DrugWatch.com; MedTech Dive. Personal naming sweep: confirmed negative.]
Adverse-SEO Artifact — Gripeo-Style Page — EXCLUDED FROM EVIDENCE
ALLEGED / NON-EVIDENTIARY. A Gripeo-style reputation-management or SEO-adjacent page was surfaced during research, characterizing Greenfield as a 'focal point of significant legal scrutiny.' This characterization is materially inconsistent with the verified judicial record: both courts ruled entirely in Greenfield's favor. The page appears to repackage the Suzuki case narrative without accurately representing the outcome. It has been excluded from citeable evidence. It is documented here solely to enable compliance consumers who encounter it in automated adverse-media screening to correctly interpret its non-evidentiary status. [ALLEGED — Gripeo-style artifact; excluded per evidence classification protocol. Rebutted by: VERIFIED PUBLIC court record.]
No FCPA, False Claims Act, Anti-Kickback, or Financial-Crime Allegation — CONFIRMED NEGATIVE
VERIFIED PUBLIC — NEGATIVE FINDING. No FCPA enforcement referral, False Claims Act qui tam or DOJ action, Anti-Kickback Statute enforcement proceeding, PACER civil docket entry beyond Suzuki, state professional license or medical board action, financial-crime allegation, AML referral, or sanctions list entry naming Andrew J. Greenfield individually has been identified across all 10 structured search angles. These negative findings formally close each search angle and are documented as confirmed negatives. [VERIFIED PUBLIC — structured sweep across PACER pointers, FDA enforcement database, DOJ press releases, OFAC SDN list, trade press. Confidence: High — with acknowledged PACER direct-access limitation.]
Adverse media assessment for Andrew J. Greenfield reflects a low-individual-risk profile. The only identified adverse media directly implicating his named role — coverage of Suzuki v. Abiomed Inc. — accurately reports a legal proceeding fully resolved in his favor. Corporate-level adverse media concerning Abiomed's FDA enforcement record and Impella recalls is documented below as organizational context. The Gripeo-style adverse-SEO artifact is mapped separately as a false-positive risk for automated screening, not as independent adverse media. Property and asset information is not applicable to this subject — the adverse media map below reflects jurisdictional context for the legal and regulatory proceedings identified.
5 identified locations · Individual adverse media: None confirmed. Corporate adverse media: Material (FDA enforcement, Class I recalls, product liability). See B4 and H2 for calibrated risk matrix.
Filter by Jurisdiction
5 properties — click a marker for details
0
Individual Adverse Proceedings (unresolved)
4
Corporate FDA Class I Recalls (2023)
1 (non-evidentiary; Gripeo-style)
Adverse-SEO Artifacts Identified
0 confirmed
Personal Enforcement Actions
Adverse-SEO Artifact Analysis and Public Persona Documentation — Andrew J. Greenfield
Adverse-SEO Artifact Analysis and Public Persona Documentation — Andrew J. Greenfield
Hover over any node to highlight its connections. The graph maps relationships between ventures, coordinated PR outlets, and targeted platforms.
First Circuit opinion (No. 19-1233) constitutes primary judicial rebuttal of adverse-SEO framing. Serves as the authoritative counter-record to any Gripeo-style characterization of Greenfield as a legal-scrutiny subject.
Corporate-level FDA enforcement coverage (warning letter; Class I recalls) generates adverse organizational context. Attribution in all identified coverage is to Abiomed Inc. as corporate entity, not to Greenfield individually.
Retirement and succession coverage provides clean public exit record, reinforcing the professional identity narrative and closing the active-executive phase of potential adverse-media exposure.
Each public claim cross-referenced against available OSINT evidence. Click any row to expand.
All claims are derived from publicly available OSINT sources. This table does not assert legal wrongdoing. Click any row to expand evidence and analyst notes.
Key documented events in chronological order. Drag to scroll.
Scroll or drag to explore — click any event for detailsSwipe to explore — tap any event for details
9 documented events · 2005 – 2025
Four-quadrant risk assessment by impact severity and likelihood of exposure.
Concentration of Four Class I Recalls in First Full Post-Acquisition Year (2023) — CORPORATE LEVEL
INFERRED (labeled as analytical pattern — not a finding of personal misconduct). Four Class I recalls — FDA's most serious classification — were issued against Abiomed Inc. in 2023, the first full calendar year following J&J's December 2022 acquisition and Greenfield's appointment as Worldwide President. This concentration in a single year is an unusual pattern warranting organizational inquiry into whether quality system deficiencies were pre-existing or emerged during the transition. Attribution: Abiomed Inc. as corporate entity. No personal enforcement nexus identified. [Source: MedTech Dive; MassDevice; FDA.gov.]
Impella Connect Marketed Without Premarket Authorization — Overlap With EVP/CCO Tenure — ORGANIZATIONAL ACCOUNTABILITY INFERENCE
INFERRED (labeled — not a finding of personal misconduct). The FDA's September 2023 determination that Abiomed had marketed the Impella Connect remote monitoring system without proper premarket authorization raises an organizational accountability question about when the product was commercially launched relative to Greenfield's EVP/CCO tenure, during which compliance was his designated organizational responsibility. The Impella Connect regulatory pathway (510(k) or PMA) and its launch date relative to Greenfield's role transitions remain an open evidence gap. No personal enforcement action has been identified. [Source: MedTech Dive.]
Gripeo-Style Adverse-SEO Artifact — Medium False-Positive Risk for Automated Screening
DOCUMENTED ARTIFACT. A Gripeo-style page was surfaced during research that characterizes Greenfield as a 'focal point of significant legal scrutiny.' This characterization is materially inconsistent with the verified judicial record — both the D. Mass. district court and the First Circuit ruled entirely in Greenfield's favor. Automated compliance screening tools that index such pages will generate a false-positive hit. Dossier consumers should treat any such hit as non-evidentiary and reference First Circuit No. 19-1233 as the authoritative record. [Artifact: ALLEGED / NON-EVIDENTIARY. Counter-record: VERIFIED PUBLIC.]
Form 4 Insider Transaction Window (Oct 2021–Oct 2023) Not Directly Reviewed — OPEN EVIDENCE GAP
OPEN EVIDENCE GAP — not an adverse finding. SEC Form 4 filings covering the recalled device distribution window (October 2021–October 2023) have not been directly retrieved and reviewed. Standard investigative protocol requires review to determine whether any equity dispositions occurred proximate to FDA inspection dates, recall initiations, or the September 2023 warning letter issuance. Anticipated outcome based on contextual evidence: exculpatory. Direct EDGAR retrieval is the priority remediation action. [Source: Open evidence gap.]
49 Deaths and 129 Injuries in FDA Recall Adverse Event Reports — CORPORATE LEVEL SEVERITY MARKER
VERIFIED PUBLIC — CORPORATE ATTRIBUTION ONLY. The December 27, 2023 Class I labeling recall adverse event report count — 49 deaths and 129 serious injuries associated with catheter perforation risk — represents a severe patient safety outcome attributable to Abiomed Inc.'s product labeling deficiency. These figures are documented here as a corporate-level severity marker that is contextually relevant to Greenfield's organizational accountability as Worldwide President during the distribution window. They do not constitute evidence of personal culpability absent a specific enforcement action, none of which has been identified. [Source: FDA.gov primary recall notice; MassDevice.]
Product Liability Litigation Scope — ONGOING, CORPORATE LEVEL — Personal Naming Sweep Incomplete
REPORTED — OPEN EVIDENCE GAP. Ongoing product-liability civil litigation related to Impella device failures is documented in trade press as of mid-2025. The full scope of active cases, any MDL consolidation proceedings, and the presence or absence of Greenfield's personal naming as a defendant have not been fully confirmed via direct PACER review. Confirmed negative finding: No case personally naming Greenfield has been identified in available sources. Direct PACER docket review is recommended to formally close this search angle. [Source: DrugWatch.com; MedTech Dive; personal naming sweep: confirmed negative via available sources.]
Retirement Announcement Primary Source Not Retrieved — Minor Documentation Gap
OPEN EVIDENCE GAP — minor. The formal primary sourcing vehicle for Greenfield's retirement announcement (press release, SEC 8-K, or LinkedIn post) has not been directly retrieved. The retirement itself is confirmed via LinkedIn and MassDevice trade press. No adverse implication is associated with this gap; it is documented as a documentation completeness issue. [Source: LinkedIn (secondary); MassDevice (secondary).]
PMDA Japan Approval Narrative — Anonymous Tip, Not Independently Corroborated
UNVERIFIED. Anonymous tip material provides a detailed narrative of Abiomed's Japanese regulatory approval process, including claimed meeting dates, regulatory agreements, and a September 2016 PMDA approval with restricted indications. None of this detail has been independently corroborated against PMDA primary sources, contemporaneous press releases, or verified documents. The tip is excluded from the evidentiary base. Verification against PMDA approval databases is required before any use of this narrative. [Evidence class: UNVERIFIED tip material.]
1. SEC Form 4 insider transaction filings for Andrew J. Greenfield covering October 2021–October 2023 (the recalled device distribution window) have not been directly retrieved from EDGAR. This is the highest-priority open gap — review required to determine whether any equity dispositions occurred proximate to FDA inspection dates, recall initiations, or the September 2023 warning letter issuance.
2. Direct FDA.gov URL for the September 2023 warning letter to Abiomed Inc. has not been retrieved. Trade press corroboration is available (MedTech Dive; MassDevice) but primary source documentation is required for publication-grade citation.
3. DEF 14A proxy filings (FY2018–FY2023) for Abiomed Inc. have not been directly retrieved from EDGAR. These are required to confirm the exact accountability scope language for each of Greenfield's role transitions (VP Healthcare Solutions → EVP/CCO → Worldwide President) and to confirm named executive officer status across all periods.
4. Direct district court docket and summary judgment order for Suzuki v. Abiomed Inc. (D. Mass.) have not been retrieved — only the First Circuit affirmance is in evidence. The district court ruling date, order text, and procedural record should be retrieved via PACER to complete the two-stage judicial record.
5. Japan PMDA approval records for Impella devices — referenced in anonymous tip material as a September 2016 approval with restricted indications — have not been independently corroborated against PMDA primary sources or contemporaneous press. This detail is currently classified as UNVERIFIED tip material and excluded from the evidentiary base.
On the full record reviewed, Andrew J. Greenfield presents as a low-individual-risk subject whose only identified adverse legal proceeding — Suzuki v. Abiomed Inc. — was resolved entirely in his favor at both the district and First Circuit appellate levels in November 2019 and has been fully dormant since that date. No personal enforcement action, criminal charge, regulatory sanction, financial-crime allegation, or civil proceeding beyond the resolved Suzuki matter has been identified against him individually across any of the ten structured search angles employed. The principal analytical complexity of this dossier is the accurate mapping of the boundary between individual risk (very low, dormant) and organizational context risk (high — documented FDA enforcement, four Class I recalls in 2023, product liability wave). As Worldwide President of Abiomed from 2022 through early 2025, Greenfield held organizational accountability for the quality and regulatory affairs functions implicated by the FDA's enforcement actions; this is a properly labeled analytical inference from his role, not a finding of personal culpability, and no regulatory or judicial body has converted this inference into a personal enforcement action. A Gripeo-style adverse-SEO artifact presents a medium false-positive risk for automated compliance screening and should be treated as non-evidentiary by any dossier consumer who encounters it, with First Circuit No. 19-1233 serving as the authoritative counter-record. Five open evidence gaps — Form 4 insider transaction review, FDA warning letter primary URL, DEF 14A proxy language, district court docket, and Japan PMDA verification — limit the confidence ceiling of this dossier to HIGH (individual risk) and MEDIUM-HIGH (organizational context completeness). Remediation of these gaps, particularly the Form 4 review, is recommended before any compliance-critical engagement decision.
This dossier is produced for due-diligence and risk-advisory purposes only. All findings are evidence-classified and labeled by source tier. No adverse claim is made against Andrew J. Greenfield individually beyond the confirmed, fully resolved Suzuki v. Abiomed Inc. litigation. Organizational-level adverse findings are attributed exclusively to Abiomed Inc. and/or Johnson & Johnson MedTech as corporate entities. Analytical inferences are explicitly labeled as such and do not constitute findings of fact. This document does not constitute legal advice. Formal sanctions database screening and PACER direct-access review are recommended supplements before any compliance-critical engagement decision.
Medium Risk · Tier B. The risk profile for Andrew J. Greenfield at the individual level is low: the sole identified legal proceeding naming his executive role was resolved entirely in his favor at both the district and appellate court level and is fully dormant, and no personal criminal, regulatory, or financial-crime exposure has been identified across any reviewed source or search angle. The elevated risk signals present in this profile are attributable to Abiomed Inc. as a corporate entity — specifically the FDA warning letter, four Class I recalls in 2023, and ongoing product-liability litigation involving the Impella device — which occurred during Greenfield's presidency and represent material organizational-context risk without established personal enforcement nexus. A residual moderate risk arises from adverse-SEO artifacts that mischaracterize the Suzuki litigation outcome and may generate false-positive results in automated compliance screening workflows, requiring manual adjudication by due-diligence reviewers.
* This report is maintained as a living investigative record. Evidence is categorized by verification status and source type. User submissions are reviewed before inclusion.
Senior Editor, Reports, based in New York. Reviews intelligence reports involving regulatory actions, compliance failures, litigation, and corporate governance.
This report is maintained as a living investigative record. Evidence is categorized by verification status and source type. User submissions are reviewed before inclusion.
Subjects, representatives, and counsel may submit additional or amended responses at any time. The channel remains open — every submission is reviewed manually before publication.
A restricted research workspace from Investigations.org — daily lead intake from twelve monitored source categories, scored and source-linked for human review.


GTV Media Group settled SEC charges for $539M after raising $452M in unregistered offerings. Founder convicted, sentenced 30 years. Investor fraud examined.
Former Binance UK head and Eqonex CEO named in dismissed SDNY securities class action. FCA raised beneficial-ownership concerns during his dual executive tenure.
Gstaad Brokers Ltd, offshore arm of FXVC/Finteractive, faces FCA enforcement, CySEC fines, licence revocation & alleged EU solicitation via Seychelles shell.
FCA-regulated eMerchantPay's auditor resigned citing governance failures. Reynisson faces alleged cybercrime links, Panama Papers listing, and regulatory blind spots.
SEC alleges Jonathan Adam ran a $61.5M crypto Ponzi scheme via GCZ Global LLC while concealing three prior felony convictions. Asset freeze imposed. Case expanding.
27 former employees allege Lubin stripped ConsenSys AG equity in a Swiss-to-Delaware restructuring. JPMorgan named co-defendant. SEC case closed, NY suit active.
A due-diligence map of the OFAC-designated Alex Saab network: Group Grand Limited across Hong Kong, Mexico and Dubai, the Saab brothers, and shells in Panama, Turkey and Colombia.
How Pennsylvania's Accelerated Rehabilitative Disposition clears a criminal charge without a conviction, and the limits that keep records visible to law enforcement and PennDOT, grounded in the Carla Risoldi diversion.
Carla Risoldi was charged in the 2015 Clairemont insurance-fraud case, then routed into diversion with no conviction. What the public record shows for due diligence.
Structured intelligence intake, watchlist tracking, custom alerts, and mobile access — and the means to underwrite the archive's independence.
Get Involved
We moderate comments to keep this a respectful and safe place. We have a zero-tolerance approach to user-to-user personal abuse. Please follow the house rules.
Participate in discussion, add context, and respond to this report.
* This discussion is moderated. Keep comments factual, relevant, and constructive. All submissions are reviewed before publication.
Submit verified tips, supporting evidence, or additional intelligence.
Request factual corrections or submit verifiable updates for this report.
* This discussion is moderated. Keep comments factual, relevant, and constructive. All submissions are reviewed before publication.
No comments yet. Be the first to comment!